Inducible Recombinase Cell Lines for Scalable Biopharmaceutical Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing biopharmaceuticals using mammalian cell lines, such as HEK293, face inefficiencies due to toxic or difficult-to-express proteins that inhibit cell proliferation, limiting scalable production and increasing costs.
Innovation Solution
Development of stably-modified cell lines with an inducible recombinase and promoter system, allowing for controlled expression of a mitogen to enhance cell proliferation followed by induction of a gene of interest for protein production, enabling scalable and efficient production of biopharmaceuticals, including difficult-to-express proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If mammalian cell lines are used to produce recombinant proteins, then biopharmaceutical production is achieved, but cell proliferation is inhibited by toxic proteins limiting scaling
Solution Approach 1:
The patent divides the production process into two distinct phases: a proliferation phase where cells multiply under mitogenic stimulation, and a production phase where toxic proteins are expressed. This temporal segmentation allows cells to reach high densities before encountering toxic effects, thereby decoupling cell growth from protein production and enabling scalable biopharmaceutical manufacturing.
Solution Approach 2:
The system performs preliminary cell proliferation before inducing toxic protein expression. By pre-expanding the cell population to high densities through controlled mitogenic stimulation, the system prepares a large cell biomass that can subsequently produce the desired biopharmaceutical at scale, overcoming the limitation of toxic proteins that would otherwise restrict cell numbers.
2Adaptability or versatility
If inducible systems based on DNA recombination are used, then controlled protein expression is achieved, but recombination events do not occur in all treated cells
Solution Approach 1:
The patent introduces a viral integrase enzyme as an intermediary mechanism to mediate DNA recombination events. This enzymatic approach, compared to traditional recombination systems, significantly increases the efficiency and consistency of integration events across the cell population, ensuring more reliable and uniform expression of the inducible gene of interest throughout the cultured cells.
3Productivity
If cells are induced to express toxic biopharmaceuticals, then protein production increases, but cell viability decreases
Solution Approach 1:
The system employs periodic action by cycling between a proliferation phase with mitogenic stimulation and a production phase with toxic protein expression. This temporal oscillation allows cells to periodically recover and maintain viability during the production phase, as they are not continuously exposed to toxic conditions, thereby sustaining both high protein production and acceptable cell viability throughout the culture process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the efficient and scalable production of biopharmaceuticals by separating cell growth from protein synthesis, enabling the production of toxic or difficult-to-express proteins while maintaining cell viability, thus overcoming previous production limitations.
Implementation Method 1
a recombination activity of the inducible recombinase comprising the transposon in the cells in the increased cell population is induced
Data Source
AI summary
Provided herein are stably-modified cell lines such as HEK293 cell lines. The cell lines are modified with an insertion, such as, a transposon containing an inducible recombinase and a promoter and one of a DNA cassette encoding an excisable mitogen, a DNA cassette encoding an inducible gene of interest or a DNA cassette encoding the excisable mitogen and the inducible gene of interest. The stably-modified cell lines are used in methods for producing a biological medical product, for example, in a scalable process for producing biopharmaceuticals.